Zhejiang DTRM Biopharma announced a $60M Series A round that will support clinical trials of its lead cancer candidate, a Bruton’s tyrosine kinase inhibitor.
January 5, 2017 -- Zhejiang DTRM Biopharma announced a $60 million Series A round that will support clinical trials of its lead cancer candidate, a Bruton’s tyrosine kinase (BTK) inhibitor. The candidate is currently in US and China Phase I trials for B cell lymphoma and chronic lymphocytic leukemia. DTRM was established in 2011 by He Wei, PhD, a returnee, and Zhejiang Hisun Pharma. The company is testing its BTK-inhibitor as a monotherapy and in combination with other drugs.
